1353625-73-6|普沙托韦|Presatovir|No data available-范德生物科技公司

普沙托韦

NMR下载 COA and HPLC MSDS下载
names：
Presatovir
CAS号：
1353625-73-6
MDL Number： No data available
MF(分子式)： C24H30ClN7O3S MW(分子量)： 532.06
EINECS:No data available Reaxys Number:No data available
Pubchem ID:58029842 Brand:BIOFOUNT

普沙托韦(1353625-73-6,Presatovir)是人类呼吸道合胞病毒（RSV）融合蛋白（F蛋白）抑制剂，普沙托韦具有潜在的抗病毒活性。普沙托韦与病毒表面的F蛋白特异性结合，从而抑制RSV F蛋白介导的与宿主细胞膜的融合并阻止病毒进入。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000866-10mg	10mg	99.9%	¥ 6076.00	¥ 6076.00		2-3天	- +	¥ 0.00
YZM000866-5mg	5mg	99.9%	¥ 3412.00	¥ 3412.00		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	普沙托韦(1353625-73-6,Presatovir);GS-5806
英文别名	Presatovir(1353625-73-6,GS-5806)
CAS号	1353625-73-6
SMILES	O=C(C(C=C(Cl)C=C1)=C1NS(C)(=O)=O)N(CCCC2)[C@@H]2C3=NN4C(N=C(N5CC[C@H](N)C5)C(C)=C4)=C3
Inchi	InChI=1S/C24H30ClN7O3S/c1-15-13-32-22(27-23(15)30-10-8-17(26)14-30)12-20(28-32)21-5-3-4-9-31(21)24(33)18-11-16(25)6-7-19(18)29-36(2,34)35/h6-7,11-13,17,21,29H,3-5,8-10,14,26H2,1-2H3/t17-,21-/m0/s1
InchiKey	GOFXWTVKPWJNGD-UWJYYQICSA-N
分子式 Formula	C24H30ClN7O3S
分子量 Molecular Weight	532.06
闪点 FP	No data available
熔点 Melting point	No data available
沸点 Boiling point	No data available
Polarizability极化度	54.8±0.5 10-24cm3
密度 Density	1.5±0.1 g/cm3
蒸汽压 Vapor Pressure	No data available
溶解度Solubility	DMSO >15 mg/ml
性状	灰白色至浅黄色固体粉末
储藏条件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

普沙托韦(1353625-73-6,Presatovir)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

Presatovir(1353625-73-6,GS-5806) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:普沙托韦(1353625-73-6,Presatovir),普沙托韦试剂,普沙托韦抑制剂,普沙托韦的纯度,普沙托韦杂质,普沙托韦的含量,普沙托韦的作用,普沙托韦的使用,普沙托韦的外观,普沙托韦的溶解度,普沙托韦的合成,普沙托韦的生产,普沙托韦的性质

产品说明	普沙托韦(1353625-73-6,Presatovir)是人类呼吸道合胞病毒（RSV）融合蛋白（F蛋白）抑制剂，普沙托韦具有潜在的抗病毒活性。
Introduction	Presatovir(1353625-73-6,普沙托韦) is an orally available inhibitor of human respiratory syncytial virus (RSV) fusion protein (F protein), with potential antiviral activity.
Application1	普沙托韦(1353625-73-6,Presatovir)可以通过阻断病毒细胞融合过程来抑制多种呼吸道合胞病毒临床分离株。
Application2	普沙托韦(1353625-73-6,Presatovir)也可以抑制融合前或融合后呼吸道合胞病毒的构象变化
Application3	Presatovir has been used in trials studying the treatment of RSV Infection, Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus Infections, and Respiratory Syncytial Virus (RSV) Infections.

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Impact of Respiratory Virus Infections in Exacerbation of Acute and Chronic Rhinosinusitis(Current Allergy and Asthma Reports,2017)

Antiviral Consideration for Transplantation Including Drug Resistance(Principles and Practice of Transplant Infectious Diseases,2019)

Recent Developments in Infectious Disease Chemotherapy: Review for Emergency Department Practitioners 2020

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session(Bone Marrow Transplantation,2018)

Respiratory Viral Infections in Transplant Recipients(Principles and Practice of Transplant Infectious Diseases,2019)

Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study
Abstract:GS-5806 is a novel, orally bioavailable RSV fusion inhibitor discovered following a lead optimization campaign on a screening hit. The oral absorption properties were optimized by converting to the pyrazolo[1,5-a]-pyrimidine heterocycle, while potency, metabolic, and physicochemical properties were optimized by introducing the para-chloro and aminopyrrolidine groups. A mean EC50 = 0.43 nM was found toward a panel of 75 RSV A and B clinical isolates and dose-dependent antiviral efficacy in the cotton rat model of RSV infection. Oral bioavailability in preclinical species ranged from 46 to 100%, with evidence of efficient penetration into lung tissue. In healthy human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a mean 4.2 log10 reduction in peak viral load and a significant reduction in disease severity compared to placebo. In conclusion, a potent, once daily, oral RSV fusion inhibitor with the potential to treat RSV infection in infants and adults is reported.

GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein
Abstract:GS-5806 is a small-molecule inhibitor of human respiratory syncytial virus fusion protein-mediated viral entry. During viral entry, the fusion protein undergoes major conformational changes, resulting in fusion of the viral envelope with the host cell membrane. This process is reproduced in vitro using a purified, truncated respiratory syncytial virus (RSV) fusion protein. GS-5806 blocked these conformational changes, suggesting a possible mechanism for antiviral activity.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开